Phase 1/2

2 trials

Sponsors

MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC, Vertex Pharmaceuticals

Conditions

clear-cell renal cell carcinoma (ccRCC) kidney cancerfibrocystic disease of the pancreas / monogeic disease

Phase 2

A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Active, not recruitingNL-OMON47700

Vertex Pharmaceuticalsfibrocystic disease of the pancreas / monogeic disease

Start: 2017-10-11Target: 10Updated: 2024-02-28

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies

Active, not recruitingNL-OMON47649

MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLCclear-cell renal cell carcinoma (ccRCC) kidney cancer

Start: 2018-03-06Target: 10Updated: 2024-02-28